Tharimmune Inc. has announced preclinical data from its expanded pipeline with HS-1940, a dual-target multispecific biologic engineered to bind to both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), and HS-3215, a dual-target biologic binding to HER2 and HER3 receptors. Both use the proprietary Epiclick technology, a multispecific antibody engineering platform.